Q-omics provides the consensus-scored RABIF profile across patient tissues and cancer cell-line models. RABIF expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RABIF is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RABIF RNA expression shows 19,665 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where RABIF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RABIF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RABIF survival associations across molecular data types. RABIF RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RABIF RNA expression–survival associations across cancer types. High RABIF expression shows unfavorable associations in ACC, UVM, KIRP, SKCM, KICH and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RABIF RNA expression.
This table summarizes RABIF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RABIF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RABIF shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LUAD, KIRC and LIHC. The HNSC box plot shows higher RABIF RNA expression in tumor versus normal tissue (log2 FC = +0.844, t-test p < 0.001).
This table shows molecular features associated with RABIF in patient tissues and cancer cell lines. In patient samples, RABIF shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RABIF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
